ea0026p288 | Pituitary | ECE2011
Bianchi A
, Tilaro L
, Valentini F
, Gargiulo P
, Poggi M
, Baldelli R
, Passeri M
, De Marinis L
Patients with acromegaly resistant to conventional drug treatment currently can advantage with GH-receptor antagonist pegvisomant. To date, at doses up to 40 mg/day, it is capable of normalizing circulating IGF1 in until 97% of patients. Here we present the multicenter experience in Rome with Pegvisomant as a therapeutic option in acromegaly. This is an observational study including a total of 61 patients (21 males and 40 females) treated with pegvisomant for up to 7 years. Of...